CR20250103A - Moduladores de la alfa-1 antitripsina - Google Patents

Moduladores de la alfa-1 antitripsina

Info

Publication number
CR20250103A
CR20250103A CR20250103A CR20250103A CR20250103A CR 20250103 A CR20250103 A CR 20250103A CR 20250103 A CR20250103 A CR 20250103A CR 20250103 A CR20250103 A CR 20250103A CR 20250103 A CR20250103 A CR 20250103A
Authority
CR
Costa Rica
Prior art keywords
alpha
antitrypsin
modulators
aatd
compositions
Prior art date
Application number
CR20250103A
Other languages
English (en)
Inventor
Michael J Boyd
Christopher David Poff
Charlene Tsay
Jr Ronald Lee Grey
Xiaoxu Wang
Jeffery Allen Gladding
Emily Elizabeth Allen
Simon Giroux
Mengqi Li
Daniel Tyler Richter
Tony Z Scott
Jr Robert F Fimognari
Kathleen Paige Sokolowsky
Jeffrey Braden Sperry
Chenlong Zhang
Brad D Maxwell
Ales Medek
Michelle Lai-Chen
Mariam Zaky
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20250103A publication Critical patent/CR20250103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)

Abstract

Nuevos compuestos, composiciones y métodos para usar y preparar los mismos, los cuales pueden ser útiles para tratar la deficiencia de alfa-1 antitripsina (AATD)
CR20250103A 2022-09-09 2023-09-08 Moduladores de la alfa-1 antitripsina CR20250103A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263405080P 2022-09-09 2022-09-09
US202363489543P 2023-03-10 2023-03-10
PCT/US2023/032282 WO2024054624A1 (en) 2022-09-09 2023-09-08 Modulators of alpha-1 antitrypsin

Publications (1)

Publication Number Publication Date
CR20250103A true CR20250103A (es) 2025-06-26

Family

ID=88237836

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250103A CR20250103A (es) 2022-09-09 2023-09-08 Moduladores de la alfa-1 antitripsina

Country Status (19)

Country Link
US (1) US20240158404A1 (es)
EP (1) EP4584261A1 (es)
JP (1) JP2025532510A (es)
KR (1) KR20250085739A (es)
CN (1) CN120166990A (es)
AU (1) AU2023338957A1 (es)
CA (1) CA3264810A1 (es)
CL (1) CL2025000614A1 (es)
CO (1) CO2025002935A2 (es)
CR (1) CR20250103A (es)
DO (1) DOP2025000055A (es)
GE (1) GEAP202516730A (es)
IL (1) IL318884A (es)
JO (1) JOP20250051A1 (es)
MX (1) MX2025002677A (es)
PE (1) PE20251573A1 (es)
TW (1) TW202421121A (es)
UY (1) UY40419A (es)
WO (1) WO2024054624A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
WO2025193777A1 (en) * 2024-03-13 2025-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of alpha-1 antitrypsin modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN115776984A (zh) 2020-04-03 2023-03-10 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1-抗胰蛋白酶调节剂的吡咯并[2,3-f]吲唑和2,4,5,10-四氮杂三环[7.3.0.03,7]十二碳-1,3(7),5,8,11-五烯衍生物

Also Published As

Publication number Publication date
DOP2025000055A (es) 2025-05-15
IL318884A (en) 2025-04-01
CL2025000614A1 (es) 2025-06-27
KR20250085739A (ko) 2025-06-12
EP4584261A1 (en) 2025-07-16
TW202421121A (zh) 2024-06-01
JOP20250051A1 (ar) 2025-03-04
US20240158404A1 (en) 2024-05-16
MX2025002677A (es) 2025-04-02
UY40419A (es) 2024-04-02
CO2025002935A2 (es) 2025-03-27
PE20251573A1 (es) 2025-06-12
WO2024054624A1 (en) 2024-03-14
AU2023338957A1 (en) 2025-02-20
CN120166990A (zh) 2025-06-17
JP2025532510A (ja) 2025-10-01
CA3264810A1 (en) 2024-03-14
GEAP202516730A (en) 2025-07-25

Similar Documents

Publication Publication Date Title
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
CR20250103A (es) Moduladores de la alfa-1 antitripsina
MX2021013993A (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina.
MX2023012245A (es) Compuestos, composiciones y metodos para el tratamiento del cancer.
MY209340A (en) Egfr inhibitor for the treatment of cancer
MY196582A (en) PD-1/PD-L1 Inhibitors
WO2020247701A3 (en) Inhibitors of sarm1
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
AU2020231934A8 (en) Compounds useful in HIV therapy
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2024004993A (es) Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
PH12022550078A1 (en) Enzyme inhibitors
CR20220004A (es) Nuevos compuestos heterocíclicos
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
MX2025003568A (es) Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap)
MX2025002519A (es) Derivados de piridazinona como degradadores de kat2 para el tratamiento de trastornos proliferativos
EP3939599A3 (en) Silicate containing compositions and methods of treatment
AU2020378127A8 (en) Compounds as CD73 inhibitors
CA3256727A1 (en) COMPOSITIONS FOR THE TREATMENT OF XLMTM
MX2025004094A (es) Inhibidores y/o degradadores de hsd17b13
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2023034914A3 (en) Methods for the prevention and treatment of synucleinopathies
CA3242747A1 (en) Plpro inhibitors